Key facts
- Respiree’s last known valuation is $10.8M (Jan 2023).
- It has raised $15.2M; the latest was Later Stage VC ($11.6M) in Feb 2026.
- Notable investors include Texas Medical Center, SEEDS Capital, Mayo Clinic Ventures, ClavystBio, Accelerate Technologies — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Respiree
- ·The full record, as it builds
Funding rounds
No funding rounds for Respiree are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Respiree
Developer of AI-based breath-cardio sensors designed to improve patient outcomes and medicine at large. The company focuses on combating chronic respiratory diseases and mental health disorders by monitoring and recognizing abnormal changes in breathing and hemodynamic variability, enabling healthcare professionals to receive alerts in case of any clinical deteriorations and offer diagnoses of cardio-respiratory diseases for their patients.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2019
- Employees
- 33
- Website
- respiree.com/
- Ownership
- Privately Held (backing)
Respiree doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Respiree shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Respiree in its N-PORT filings yet. We sweep new filings monthly.